A psychedelic nasal spray requiring a much shorter period of clinical supervision has shown promise against treatment-resistant depression, giving biotechs hope that this type of drug will become a viable option for healthcare systems to use for mental health conditions.
一种需要更短临床监督期的致幻剂鼻喷雾剂已显示出对抗难治性抑郁症的潜力，这让生物技术公司看到了希望，即此类药物有望成为医疗系统用于治疗精神疾病的可行选择。
您已阅读8%（348字），剩余92%（4222字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。